Karsten Fischer, BioMedPartners AG commented. ‘Alongside the unique small volume format, this technique is enabling research, development and potential diagnostic questions even, so far inaccessible.’ Alec Rauschenbusch, Handling Partner of Grazia Collateral GmbH: ‘With its highly innovative multiplexing system, AYOXXA is setting new requirements for applications and analysis of high-worth biological samples in the area of medical analysis and pharmacological screening.’ Additionally, the business announces that Andreas Richter will take over the function as CFO in AYOXXA's Executive Management Team, effective January 1st 2015.Total revenues for the 2010 period consisted mainly of $16.0 million of Feraheme net item revenues, $1.5 million in collaboration revenues linked to the amortization of the upfront payment from Takeda and $1.0 million in collaboration revenues connected with reimbursement from Takeda, primarily related to costs associated with the MAA filing and certain other clinical and regulatory costs incurred by AMAG through the second quarter. The upsurge in revenues this year 2010 over the similar 2009 period was primarily attributable to Feraheme product product sales following its U.S.
- According to new Northwestern Medicine research.
- Abortion By Pill: How Is Its Feasible For You?
- Lifelong Wellness: The Bioscience of Ageing.
- Let me clarify three items before we even enter the tale: 1 NO.
- Abnormal cell division explained Why do some malignancy cells divide not into two.
- Accelera Innovations.
- ACOEM honors American Express with prestigious health insurance and safety award American Express.
- Compared to more than 75 % who were covered in 2004.
- A Permanent Remedy To Arthritis Arthritis is a heart rendering problem really.
- According to a new statement released by the U.
- 1 The retractions came only weeks after BioMed Central.
- 700 adult survivors of childhood cancer.
- It is hard to stop acne from showing up often.
- A favorite supplement.
- Agriculture expense in developing countries must boost by 50 percent to feed 9.
- 3D scaffolds bring hope for lung regeneration In end-stage lung disease.
- Adoptive T-cell therapy might help in treating liver cancer.